Urinary Incontinence - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464084 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Urinary Incontinence - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2019, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Urinary Incontinence - Overview

Urinary Incontinence - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Urinary Incontinence - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Urinary Incontinence - Companies Involved in Therapeutics Development

Allergan Plc

Beech Tree Labs Inc

Crystec Ltd

FemmePharma Global Healthcare Inc

Innovacell Biotechnologie AG

Pfizer Inc

Revance Therapeutics Inc

Saniona AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Taris Biomedical LLC

Urinary Incontinence - Drug Profiles

BTL-hs - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICES-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

litoxetine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prof-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolterodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Urinary Incontinence - Dormant Projects

Urinary Incontinence - Discontinued Products

Urinary Incontinence - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464084 | GMDHC11420IDB

Number of Pages

72

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
28-02-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Urinary Incontinence - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.